Literature DB >> 33910847

Validation of the Effectiveness of Neutrophil-to-lymphocyte Ratio (NLR) as a Predictive Factor in Patients Undergoing Prostate Biopsy With Prostate Specific Antigen (PSA) Between 4.0 and 10.0 ng/ml.

Hiroshi Masuda1, Kosuke Mikami2, Kotaro Otsuka2, Kyokusin Hou2, Takahito Suyama2, Kazuhiro Araki2, Satoko Kojima2, Yukio Naya2.   

Abstract

BACKGROUND/AIM: This study aimed to access the effectiveness of serum neutrophil-to-lymphocyte ratio (NLR) in patients undergoing prostate needle biopsy with a prostate specific antigen (PSA) between 4.0 and 10.0 ng/ml. PATIENTS AND METHODS: A total of 633 cases were eligible. We evaluated several factors including age, PSA, PSA-density (PSAD), platelet-to-lymphocyte ratio (PLR) and NLR in the presence or absence of prostate cancer (PCa), retrospectively. We evaluated statistically the associations between each factor and pathological findings or Gleason score.
RESULTS: A total of 201 were evaluated in this study. Regarding the presence or absence of prostate cancer, there were statistically significant differences in age, PSA levels, PSAD, the PLR and NLR. The mean NLR value of the patients with PCa was significantly lower compared to the entire cohort. Multivariate analysis showed that age, PSAD, and NLR were independent risk factors predicting PCa.
CONCLUSION: For patients having a PSA between 4.0 and 10.0 ng/ml, NLR was a predicting factor of PCa prior to prostate needle biopsy and an effective biomarker and useful tool for avoiding unnecessary biopsies. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Neutrophil-to-lymphocyte ratio; gray zone; prostate biopsy; prostate cancer

Mesh:

Substances:

Year:  2021        PMID: 33910847      PMCID: PMC8193316          DOI: 10.21873/invivo.12422

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  24 in total

1.  Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma.

Authors:  Yoshio Ohno; Jun Nakashima; Makoto Ohori; Tadashi Hatano; Masaaki Tachibana
Journal:  J Urol       Date:  2010-09       Impact factor: 7.450

2.  Low serum neutrophil count predicts a positive prostate biopsy.

Authors:  K Fujita; R Imamura; G Tanigawa; M Nakagawa; T Hayashi; N Kishimoto; M Hosomi; S Yamaguchi
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-07-10       Impact factor: 5.554

3.  Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.

Authors:  Ozgur Haki Yuksel; Ahmet Urkmez; Serkan Akan; Caglar Yldirim; Ayhan Verit
Journal:  Asian Pac J Cancer Prev       Date:  2015

Review 4.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

Authors:  Campbell S D Roxburgh; Donald C McMillan
Journal:  Future Oncol       Date:  2010-01       Impact factor: 3.404

5.  Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.

Authors:  Volkan Caglayan; Efe Onen; Sinan Avci; Murat Sambel; Metin Kilic; Sedat Oner; Mustafa Murat Aydos; Halil Emre Yıldız
Journal:  Arch Ital Urol Androl       Date:  2019-01-17

6.  Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.

Authors:  Tadayuki Kou; Masashi Kanai; Michio Yamamoto; Peng Xue; Yukiko Mori; Yasushi Kudo; Akira Kurita; Norimitsu Uza; Yuzo Kodama; Masanori Asada; Michiya Kawaguchi; Toshihiko Masui; Masaki Mizumoto; Shujiro Yazumi; Shigemi Matsumoto; Kyoichi Takaori; Satoshi Morita; Manabu Muto; Shinji Uemoto; Tsutomu Chiba
Journal:  Int J Clin Oncol       Date:  2015-06-28       Impact factor: 3.402

7.  Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.

Authors:  Tanja Langsenlehner; Eva-Maria Thurner; Sabine Krenn-Pilko; Uwe Langsenlehner; Tatjana Stojakovic; Armin Gerger; Martin Pichler
Journal:  World J Urol       Date:  2015-01-24       Impact factor: 4.226

8.  Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.

Authors:  Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

Review 9.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

Review 10.  Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.

Authors:  Xiaobin Gu; Xianshu Gao; Xiaoying Li; Xin Qi; Mingwei Ma; Shangbin Qin; Hao Yu; Shaoqian Sun; Dong Zhou; Wen Wang
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.